CN Mobile Logo

Search form


Renal Cell Carcinoma

Renal Cell Carcinoma

The addition of the IMA901 vaccine to sunitinib for the first-line treatment of metastatic renal cell carcinoma did not improve overall survival.

Treatment with cabozantinib resulted in significantly improved PFS and overall response vs sunitinib for patients with metastatic renal cell carcinoma.

Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.

The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).

Patients with metastatic RCC and a BMI of 25 or greater had significantly longer overall survival compared with patients with a BMI of less than 25, according to the results of a recent study.

The combination of bevacizumab and everolimus had efficacy in patients with unclassified non–clear cell renal cell carcinoma characterized by papillary features, resulting in an objective response rate of 43%.

Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.


Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.